SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Nektar Therapeutics (CA) Announces Start of Enrollment in Phase 2 Study of NKTR-181, a Novel Opioid Analgesic Molecule, for Treatment of Chronic Pain